Cramer Rosenthal Mcglynn LLC boosted its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 217.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 318,942 shares of the medical research company’s stock after purchasing an additional 218,512 shares during the quarter. Bio-Rad Laboratories makes up approximately 1.1% of Cramer Rosenthal Mcglynn LLC’s holdings, making the stock its 23rd biggest position. Cramer Rosenthal Mcglynn LLC owned 1.08% of Bio-Rad Laboratories worth $72,180,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. BlackRock Inc. grew its holdings in Bio-Rad Laboratories by 9,953.4% during the 1st quarter. BlackRock Inc. now owns 1,733,111 shares of the medical research company’s stock valued at $345,478,000 after buying an additional 1,715,872 shares in the last quarter. FMR LLC raised its position in shares of Bio-Rad Laboratories by 237.4% during the second quarter. FMR LLC now owns 711,313 shares of the medical research company’s stock valued at $160,978,000 after buying an additional 500,513 shares during the last quarter. Royal Bank of Canada raised its position in shares of Bio-Rad Laboratories by 101.2% during the second quarter. Royal Bank of Canada now owns 3,324 shares of the medical research company’s stock valued at $752,000 after buying an additional 281,264 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Bio-Rad Laboratories by 93.1% in the second quarter. Wells Fargo & Company MN now owns 523,876 shares of the medical research company’s stock worth $118,557,000 after buying an additional 252,643 shares in the last quarter. Finally, Laurion Capital Management LP lifted its holdings in shares of Bio-Rad Laboratories by 104.2% in the second quarter. Laurion Capital Management LP now owns 6,572 shares of the medical research company’s stock worth $1,487,000 after buying an additional 163,172 shares in the last quarter. Institutional investors and hedge funds own 62.84% of the company’s stock.

BIO has been the subject of a number of research reports. Zacks Investment Research lowered shares of Bio-Rad Laboratories from a “hold” rating to a “sell” rating in a research report on Thursday, August 10th. BidaskClub raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday, June 22nd. Jefferies Group LLC reiterated a “buy” rating and issued a $275.00 price target on shares of Bio-Rad Laboratories in a report on Friday, July 14th. Wells Fargo & Company assumed coverage on shares of Bio-Rad Laboratories in a report on Thursday, July 13th. They issued an “outperform” rating and a $250.00 price target on the stock. Finally, Deutsche Bank AG upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating and decreased their price target for the stock from $220.00 to $195.00 in a research note on Wednesday, June 28th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. Bio-Rad Laboratories presently has a consensus rating of “Buy” and an average target price of $240.80.

COPYRIGHT VIOLATION NOTICE: “Bio-Rad Laboratories, Inc. (BIO) Holdings Lifted by Cramer Rosenthal Mcglynn LLC” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/bio-rad-laboratories-inc-bio-holdings-lifted-by-cramer-rosenthal-mcglynn-llc/1605648.html.

Bio-Rad Laboratories, Inc. (NYSE:BIO) traded down 0.43% during mid-day trading on Tuesday, reaching $221.87. The company’s stock had a trading volume of 35,949 shares. The firm’s 50 day moving average is $220.53 and its 200-day moving average is $219.66. Bio-Rad Laboratories, Inc. has a 12-month low of $154.89 and a 12-month high of $242.79. The company has a market cap of $6.58 billion, a PE ratio of 438.48 and a beta of 0.91.

In other Bio-Rad Laboratories news, EVP Michael Crowley sold 700 shares of the stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $215.91, for a total transaction of $151,137.00. Following the completion of the transaction, the executive vice president now owns 2,060 shares of the company’s stock, valued at $444,774.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 28.29% of the stock is currently owned by insiders.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.